局部晚期宫颈癌盆腔及腹主动脉旁淋巴结评估中的[18F]FDG-PET或PET/CT:系统综述
该系统综述纳入12项研究共778例10-85岁局部晚期宫颈癌患者,汇总[18F]FDG-PET(CT)检测盆腔和腹主动脉旁淋巴结转移的敏感度与特异度,并计算不同患病率下的阳性与阴性预测值。盆腔淋巴结汇总敏感度0.88、特异度0.93;腹主动脉旁淋巴结汇总敏感度0.40、特异度0.93。结论认为预测值随患病率升高而改善,制定治疗策略时应考虑患病率与预测值。
要点
- 盆腔淋巴结:汇总敏感度0.88(95%CI 0.40-0.99),特异度0.93(95%CI 0.85-0.97)。
- 腹主动脉旁淋巴结:汇总敏感度0.40(95%CI 0.18-0.66),特异度0.93(95%CI 0.91-0.95)。
- 患病率0.15时盆腔淋巴结PPV 0.68、NPV 0.98;患病率0.65时PPV 0.96、NPV 0.81。
核心结论
- [18F]FDG-PET(CT)显示局部晚期宫颈癌淋巴结转移的阳性预测值和阴性预测值随患病率升高而改善。
- 在依据[18F]FDG-PET(CT)制定治疗策略时,应考虑患病率与预测值。
研究设计与样本
- 系统综述,检索MEDLINE和EMBASE,评估质量特征。
- 纳入12项研究,共778例患者,年龄10-85岁。
- 采用logit变换计算汇总敏感度、特异度及95%CI,并由贝叶斯方法确定验后概率。
主要发现
- 盆腔淋巴结:汇总敏感度0.88(95%CI 0.40-0.99),特异度0.93(95%CI 0.85-0.97),LR+ 11.90(95%CI 5.32-26.62),LR- 0.13(95%CI 0.01-1.08)。
- 盆腔淋巴结:患病率0.15时PPV 0.68、NPV 0.98;患病率0.65时PPV 0.96、NPV 0.81。
- 腹主动脉旁淋巴结:汇总敏感度0.40(95%CI 0.18-0.66),特异度0.93(95%CI 0.91-0.95),LR+ 6.08(95%CI 2.90-12.78),LR- 0.64(95%CI 0.42-0.99)。
- 腹主动脉旁淋巴结:患病率0.17时PPV 0.55、NPV 0.88;患病率0.50时PPV 0.86、NPV 0.61。
临床怎么用
- 作者认为,在依据[18F]FDG-PET(CT)制定治疗策略时,应考虑患病率与预测值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imaging is essential in detecting lymph node metastases for radiotherapy treatment planning in locally advanced cervical cancer (LACC). There are not many data on the performance of [18F]FDG-PET(CT) in showing lymph node metastases in LACC. We pooled sensitivity and specificity of [18F]FDG-PET(CT) for detecting pelvic and/or para-aortic lymph node metastases in patients with LACC. Also, the positive and negative posttest probabilities at high and low levels of prevalence were determined. METHODS: MEDLINE and EMBASE searches were performed and quality characteristics assessed. Logit-sensitivity and logit-specificity estimates with corresponding standard errors were calculated. Summary estimates of sensitivity and specificity with corresponding 95% confidence intervals (CIs) were calculated by anti-logit transformation. Positive and negative likelihood ratios (LRs) were calculated from the mean logit-sensitivity and mean logit-specificity and the corresponding standard errors. The posttest probabilities were determined by Bayesian approach. RESULTS: Twelve studies were included with a total of 778 patients aged 10-85 years. For pelvic nodes, summary estimates of sensitivity, specificity, LR+ and LR- were: 0.88 (95%CI: 0.40-0.99), 0.93 (95%CI: 0.85-0.97), 11.90 (95%CI: 5.32-26.62) and 0.13 (95%CI: 0.01-1.08). At the lowest prevalence of 0.15 the positive predictive value (PPV) and negative predictive value (NPV) were 0.68 and 0.98, at the highest prevalence of 0.65, 0.96 and 0.81. For the para-aortic nodes, the summary estimates of sensitivity, specificity LR+ and LR- were: 0.40 (95%CI: 0.18-0.66), 0.93 (95%CI: 0.91-0.95), 6.08 (95%CI: 2.90-12.78) and 0.64 (95%CI: 0.42-0.99), respectively. At the lowest prevalence of 0.17 the PPV and NPV were 0.55 and 0.88, at the highest prevalence of 0.50, 0.86 and 0.61. CONCLUSION: The PPV and NPV of [18F]FDG-PET(CT) showing lymph node metastases in patients with LACC improves with higher prevalence. Prevalence and predictive values should be taken into account when determining therapeutic strategies based on [18F]FDG-PET(CT).
引用
- Adam JA, van Diepen PR, Mom CH, et al. [18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature. Gynecol Oncol. 2020. PMID: 32921477. doi:10.1016/j.ygyno.2020.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。